HMGCR is upregulated by E2F1, driving ferroptosis resistance by reducing oxidative damage triggered by T cell-based therapy. Notably, targeting HMGCR restores ferroptosis sensitivity in immune-refractory tumors, enhancing response to PD-1 blockade as well as adoptive T cell transfer therapy.
- Sung Wook Son
- Hyo-Jung Lee
- Kwon-Ho Song